Please login to the form below

Not currently logged in
Email:
Password:

nalmefene

This page shows the latest nalmefene news and features for those working in and with pharma, biotech and healthcare.

Acorda acquires Biotie to expand in Parkinson's disease

Acorda acquires Biotie to expand in Parkinson's disease

Biotie also has a royalty stream from Lundbeck's sales of Selincro(nalmefene), which was launched in 2013 for the treatment of alcohol dependency.

Latest news

More from news
Approximately 5 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Pharma deals during September 2012 Pharma deals during September 2012

    from 2006 for Selincro (nalmefene), a novel opioid system modulator to treat alcohol dependence. Linked to this investment, the royalty rates in countries outside Europe and the US have been reduced

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics